BioCryst Pharmaceuticals provided a corporate update during reporting of financial results for the second quarter ended June 30, 2023
Charlie Gayer, Chief Commercial Officer of BioCryst, commented: “The significant step-up in revenue we expected and achieved in the second quarter reflects the continued strong growth in patients taking ORLADEYO, the normal seasonality in revenue that follows first quarter prescription reauthorizations, and our steady improvement in helping patients get to reimbursed therapy.
“We recently attended the HAEA summit, attended by 1,200 patients and family members. Their strong interest and enthusiasm gave us even more confidence in our expectations for sustained long-term demand for ORLADEYO in the U.S. and globally.”
Jon Stonehouse, President and Chief Executive Officer of BioCryst, said: “Our strong second quarter keeps us firmly on track to achieve no less than $320 million in ORLADEYO revenue this year as our base of patients grows larger and larger every quarter. While ORLADEYO revenues continue to grow, we are also excited to host an R&D day in November to introduce new molecules and programs from our discovery platform that have the potential to replicate or exceed the success of ORLADEYO.”
Sales from outside the U.S. contributed 10.1 percent of global ORLADEYO net revenues in the second quarter.
ORLADEYO® (berotralstat) is an oral, once-daily treatment for the prevention of hereditary angioedema (HAE) attacks.
(Source: BioCryst Pharmaceuticals)
